Literature DB >> 28249261

Crosstalk between Bile Acids and Gut Microbiota and Its Impact on Farnesoid X Receptor Signalling.

Annika Wahlström1, Petia Kovatcheva-Datchary, Marcus Ståhlman, Fredrik Bäckhed, Hanns-Ulrich Marschall.   

Abstract

BACKGROUND: The gut microbiota has a substantial impact on health and disease. The human gut microbiota influences the development and progression of metabolic diseases; however, the underlying mechanisms are not fully understood. The nuclear farnesoid X receptor (FXR), which regulates bile acid homeostasis and glucose and lipid metabolism, is activated by primary human and murine bile acids, chenodeoxycholic acid and cholic acid, while rodent specific primary bile acids tauromuricholic acids antagonise FXR activation. The gut microbiota deconjugates and subsequently metabolises primary bile acids into secondary bile acids in the gut and thereby changes FXR activation and signalling. Key Message: Mouse models have been used to study the crosstalk between bile acids and the gut microbiota, but the substantial differences in bile acid composition between humans and mice need to be considered when interpreting data from such studies and for the development of so-called humanised mouse models.
CONCLUSION: It is of special importance to elucidate how a human gut microbiota influences bile acid composition and FXR signalling in colonised mice.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28249261     DOI: 10.1159/000450982

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  27 in total

Review 1.  Thinking Outside the Cereal Box: Noncarbohydrate Routes for Dietary Manipulation of the Gut Microbiota.

Authors:  Aspen T Reese; Rachel N Carmody
Journal:  Appl Environ Microbiol       Date:  2019-05-02       Impact factor: 4.792

Review 2.  Microbial modulation of cardiovascular disease.

Authors:  J Mark Brown; Stanley L Hazen
Journal:  Nat Rev Microbiol       Date:  2018-01-08       Impact factor: 60.633

Review 3.  Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.

Authors:  Suzanne R Sharpton; Veeral Ajmera; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-07       Impact factor: 11.382

4.  Acute Changes of Bile Acids and FGF19 After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass.

Authors:  Yutao Chen; Jun Lu; Reza Nemati; Lindsay D Plank; Rinki Murphy
Journal:  Obes Surg       Date:  2019-11       Impact factor: 4.129

5.  Bile acid signaling and bariatric surgery.

Authors:  Jingyan Tian; Silvia Huang; Siming Sun; Lili Ding; Eryun Zhang; Wendong Huang
Journal:  Liver Res       Date:  2017-12

6.  Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during Clostridioides difficile Infection by Altering Gut Bile Acids.

Authors:  Jenessa A Winston; Alissa J Rivera; Jingwei Cai; Rajani Thanissery; Stephanie A Montgomery; Andrew D Patterson; Casey M Theriot
Journal:  Infect Immun       Date:  2020-05-20       Impact factor: 3.441

7.  Circulating microbiota-derived metabolites: a "liquid biopsy?

Authors:  Gemma Aragonès; Marina Colom-Pellicer; Carmen Aguilar; Esther Guiu-Jurado; Salomé Martínez; Fàtima Sabench; José Antonio Porras; David Riesco; Daniel Del Castillo; Cristóbal Richart; Teresa Auguet
Journal:  Int J Obes (Lond)       Date:  2019-08-06       Impact factor: 5.095

8.  Impact of Microbiome on Hepatic Metabolizing Enzymes and Transporters in Mice during Pregnancy.

Authors:  Lyrialle W Han; Lu Wang; Yuanyuan Shi; Joseph L Dempsey; Olesya V Pershutkina; Moumita Dutta; Theo K Bammler; Julia Y Cui; Qingcheng Mao
Journal:  Drug Metab Dispos       Date:  2020-06-04       Impact factor: 3.922

Review 9.  Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease.

Authors:  Marco Poeta; Luca Pierri; Pietro Vajro
Journal:  Children (Basel)       Date:  2017-08-02

Review 10.  Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review.

Authors:  Jacqueline Hoozemans; Maurits de Brauw; Max Nieuwdorp; Victor Gerdes
Journal:  Metabolites       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.